Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trinity BiotechTRIB -3.45%38 EV-to-EBITDA is -6.59 as of Jul. 29, 2026. GuruFocus rates TRIB with a GF Score™ of 38/100 and a GF Value™ of $22.72 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Trinity Biotech's enterprise value is $140.96 Mil.
Trinity Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.38 Mil. Therefore, Trinity Biotech's EV-to-EBITDA for today is -6.59.
The historical rank and industry rank for Trinity Biotech's EV-to-EBITDA or its related term are showing as below:
TRIB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.79 Med: -5.28 Max: 105.29
Current: -6.59
During the past 13 years, the highest EV-to-EBITDA of Trinity Biotech was 105.29. The lowest was -10.79. And the median was -5.28.
TRIB's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs TRIB: -6.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Trinity Biotech's PE Ratio (TTM) for today is calculated as:
Trinity Biotech's share price for today is $12.0201.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-60.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Trinity Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's EV-to-EBITDA falls into.
Trinity Biotech's current Enterprise Value is $140.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trinity Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a EV-to-EBITDA of -6.59 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trinity Biotech. According to the industry distribution chart, Trinity Biotech ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Trinity Biotech's EV-to-EBITDA too high?
Trinity Biotech's current EV-to-EBITDA is -6.59. Based on the distribution chart, Trinity Biotech ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's EV-to-EBITDA compare to STME and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #999999 out of 512 companies for EV-to-EBITDA. This places Trinity Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 14.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trinity Biotech. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current EV-to-EBITDA is -6.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $22.72, compared to a current price of $12.02 — trading 47.1% below its estimated fair value. The current EV-to-EBITDA is -6.59. Trinity Biotech's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current EV-to-EBITDA is -6.59 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $12.02 is trading 47.1% below its estimated GF Value™ of $22.72.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
EV-to-EBITDA: -6.59
GF Value™: $22.72 vs. price of $12.02 (47.1% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
38GF Score
Get the complete analysis for TRIB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
